News AstraZeneca Pharma India Limited NSE India S.E.

Equities

ASTRAZEN

INE203A01020

Delayed NSE India S.E. Other stock markets 01:06:42 2024-04-25 am EDT			5-day change	1st Jan Change
5,306 ^INR	+0.40%		+1.49%	-4.06%

Apr. 08	AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director	CI
Mar. 25	AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director	Apr. 08	CI
AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024	Mar. 25	CI
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India	Mar. 11	MT
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India	Mar. 11	CI
Astrazeneca Pharma India Limited Announces Board Changes	Feb. 19	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
AstraZeneca Pharma India Limited Announces Board Changes	Feb. 08	CI
AstraZeneca Pharma India Limited Announces Directorate Appointments	Feb. 07	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion	Jan. 21	MT
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024	Dec. 21	MT
India's Nifty set for muted open after steep drop	Dec. 20	RE
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)	Nov. 09	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab	23-10-02	MT
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab	23-09-30	CI
AstraZeneca Pharma India Limited Announces Management Changes	23-09-29	CI
Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director	23-09-29	CI
AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023	23-09-15	CI
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023	23-08-17	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AstraZeneca Pharma India Limited NSE India S.E.

Equities

ASTRAZEN

INE203A01020

Summary

Filters